Sandip P. Patel, MD
Immunotherapy’s introduction into the field of non–small cell lung cancer has revolutionized the treatment landscape, most recently following the phase III results of clinical trials such as PACIFIC and KEYNOTE-189, said Sandip P. Patel, MD. Yet, clinicians are working to refine existing and emerging immunologic agents.
State of the Science Summit™ on Non–Small Cell Lung Cancer, Patel, a medical oncologist and assistant professor of medicine at the University of California, San Diego, discussed existing and emerging immunotherapy approaches for patients with locally advanced and metastatic NSCLC.
OncLive: Please provide an overview of your presentation.
Cancer immunotherapy has revolutionized a variety of different cancers, including NSCLC. There is a wealth of options for our patients. Historically, these options had been chemotherapy. In the age of immunotherapy, including anti–PD-1 agents, we see a variety of different therapeutics in different disease stages.
... to read the full story